Table 3.
Multivariate regression analysis showing PASI90 achievement rates at week 12 and week 24 in patients with a BMI < 30 and a BMI ≥ 30 kg/m2
| Variable | PASI90 at week 12 | PASI90 at week 24 | ||||
|---|---|---|---|---|---|---|
| Odds ratio | P-value | 95% CI | Odds ratio | P-value | 95% CI | |
| BMI < 30 kg/m2 | ||||||
| Etanercept | 0.64 | 0.100 | 0.37–1.09 | 0.87 | 0.603 | 0.51–1.48 |
| Ixekizumab | 1.94 | 0.020 | 1.11–3.38 | 4.07 | 0.000 | 2.20–7.53 |
| Secukinumab | 7.16 | 0.000 | 3.76–13.6 | 7.53 | 0.000 | 3.78–14.9 |
| Ustekinumab | 2.40 | 0.003 | 1.36–4.24 | 2.95 | 0.000 | 1.62–5.37 |
| Psoriatic arthritis | 1.75 | 0.009 | 1.14–2.67 | 2.21 | 0.000 | 1.42–3.46 |
| Sex | 1.31 | 0.142 | 0.91–1.88 | 1.26 | 0.236 | 0.86–1.85 |
| Age | 0.99 | 0.125 | 0.98–1.00 | 0.99 | 0.565 | 0.98–1.01 |
| Previous biological therapies | 0.61 | 0.012 | 0.41–0.89 | 0.46 | 0.000 | 0.30–0.69 |
| Baseline PASI | 0.99 | 0.319 | 0.96–1.01 | 0.99 | 0.458 | 0.96–1.02 |
| BMI ≥ 30 kg/m2 | ||||||
| Etanercept | 0.46 | 0.166 | 0.16–1.38 | 0.72 | 0.534 | 0.26–2.00 |
| Ixekizumab | 0.86 | 0.800 | 0.26–2.81 | 0.79 | 0.693 | 0.25–2.54 |
| Secukinumab | 1.79 | 0.347 | 0.53–6.07 | 1.17 | 0.797 | 0.35–3.94 |
| Ustekinumab | 1.05 | 0.914 | 0.42–2.61 | 1.36 | 0.518 | 0.54–3.42 |
| Psoriatic arthritis | 1.22 | 0.594 | 0.59–2.53 | 1.50 | 0.275 | 0.72–3.11 |
| Sex | 1.11 | 0.788 | 0.51–2.45 | 1.48 | 0.327 | 0.68–3.21 |
| Age | 1.01 | 0.719 | 0.98–1.04 | 1.01 | 0.527 | 0.98–1.04 |
| Previous biological therapies | 0.75 | 0.447 | 0.36–1.57 | 1.05 | 0.904 | 0.50–2.18 |
| Baseline PASI | 1.05 | 0.064 | 0.99–1.10 | 1.04 | 0.146 | 0.99–1.09 |
BMI body mass index, CI confidence interval, PASI Psoriasis Area and Severity Index